Form 4: bioAffinity Technologies CEO Maria Zannes Reports Acquisition of Restricted Stock
SEC Form 4 Filing
Maria Zannes, President & CEO of bioAffinity Technologies, reports the acquisition of 37,037 shares of restricted common stock.
Summary
- On January 10, 2025, Maria Zannes, the President & CEO of bioAffinity Technologies, acquired 37,037 shares of common stock.
- These shares were granted as restricted stock.
- The restricted shares vest pro rata on a monthly basis over 12 months, starting February 10, 2025.
- Following this transaction, Ms. Zannes directly owns 280,359 shares of bioAffinity Technologies common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock ownership change. The acquisition of shares by the CEO could be interpreted slightly positively, but it's not a major event.
Positives
- The CEO's acquisition of restricted stock could be seen as a positive sign, aligning her interests with those of the shareholders.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock. It provides transparency into the ownership positions of key individuals.
Stakeholder Impact
- Shareholders may view the CEO's increased stake as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of transaction: Maria Zannes acquired 37,037 shares of restricted common stock. |
| 02/10/2025 | Vesting start date: Restricted shares vest pro rata on a monthly basis for 12 months commencing on this date. |
| 01/14/2025 | Date of report: Maria Zannes signed the Form 4 report. |
Keywords
bioAffinity Technologies, Maria Zannes, restricted stock, Form 4, BIAF, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.